In Treatment

In Treatment

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss if there is a best systemic therapy option for a patient with advanced non-squamous NSCLC, low PD-L1 and no driver mutation.
Cancer Journey:
Cancer Type:
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal approach for a fit patient with advanced squamous NSCLC and low tumor PD-L1 expression.
Cancer Journey:
Cancer Type:
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the treatment choice between targeted therapy and immunotherapy in a patient with an EGFR Mutation and high PDL-1.
Cancer Journey:
Cancer Type:
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss a frail patient with metastatic squamous NSCLC with low tumor PD-L1 expression, and the best treatment approach for this patient.
Cancer Journey:
Cancer Type:
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss treating a patient with rapidly progressing lung adenocarcinoma and high tumor PD-L1 expression.
Cancer Journey:
Cancer Type:

Articles

To many, the recent FDA approval of a combination of chemotherapy and concurrent immunotherapy for the vast majority of patients with advanced (metastatic) non-squamous non-small cell lung cancer (NSCLC) probably seems like a great idea.
Cancer Journey:
Cancer Type:
Disease Learning:
Dr. Jonathan Goldman joins GRACE to explain why carboplatin, pemetrexed and pembrolizumab has become his new go-to regimen for first-line non-squamous NSCLC treatment.
Cancer Journey:
Cancer Type:
Disease Learning:
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are...
Cancer Journey:
Cancer Type:
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
Cancer Journey:
Cancer Type:
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce John Cherol, EGFR patient.
Cancer Journey:
Cancer Type:
Disease Learning:

Community Forum

This question is not for a specific patient, it is designed to understand how oncologists would approach this problem. There’s a 50 year old stage...
Cancer Journey:
Cancer Type:
My wife is experiencing a second time brain tumor recurrence. She had her first occipital craniotomy back in 2011. On late Oct 2013 she began to...
Cancer Journey:
Cancer Type:
Has anyone any information on obtaining and using Vaxira, the Cuban drug, for stage 4 advanced NSCLC? Not sure if US citizens can still travel to...
Cancer Journey:
Cancer Type:
My wife has come a long way with Stage IV lung cancer since 2010. She has now developed acquired resistance to Tarceva. Gene sequence of biopsy from...
Cancer Type:
Hi Grace community, Thank you for the extensive information and great support on your website. It seems that after 9,5 years I have developed...
Cancer Journey:
Cancer Type: